Nurix Therapeutics, Inc.
NRIX · XNASCIK 1549595fmd_1HMS2K9FQS7CRNCXE80KQEWJVSManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Dec 01, 2018 to Aug 31, 2026, 31 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 31 | 18 | 30 | 39 | 77 | 55 | 84 |
| Research and development | 45 | 66 | 116 | 184 | 189 | 222 | 317 |
| Total operating expenses | 53 | 83 | 148 | 222 | 232 | 268 | 370 |
| Operating income | (22) | (65) | (118) | (184) | (155) | (213) | (286) |
| Interest and investment income | 1 | 1 | 1 | 4 | 11 | 20 | 22 |
| Income before taxes | (21) | (64) | (117) | (180) | (144) | (193) | (264) |
| Income tax expense | 0 | (21) | 0 | 0 | 0 | 0 | 1 |
| Net income from continuing operations | (22) | (43) | (117) | (180) | (144) | (194) | (264) |
| Net income | (22) | (43) | (117) | (180) | (144) | (194) | (264) |